Jounce Therapeutics to Announce Second Quarter 2021 Financial Results and Host a Conference Call on Thursday, August 5, 2021
July 29 2021 - 8:00AM
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers, today announced that it
will report second quarter 2021 financial results and provide a
corporate update before market open on Thursday, August 5, 2021.
Jounce Therapeutics’ management team will host a live conference
call and webcast at 8:00am ET.
Conference Call and WebcastTo
access the conference call, please dial (866) 916-3380 (domestic)
or (210) 874-7772 (international) and refer to conference ID
4291658. The live webcast can be accessed under “Events &
Presentations” in the Investors and Media section of Jounce’s
website at www.jouncetx.com. The webcast will be archived and made
available for replay on the company’s website approximately two
hours after the call and will be available for 30 days
thereafter.
About Jounce TherapeuticsJounce
Therapeutics, Inc. is a clinical-stage immunotherapy company
dedicated to transforming the treatment of cancer by developing
therapies that enable the immune system to attack tumors and
provide long-lasting benefits to patients through a
biomarker-driven approach. Jounce currently has multiple
development stage programs ongoing while simultaneously advancing
additional early-stage assets from its robust discovery engine
based on its Translational Science Platform. Jounce’s highest
priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist
shown to reprogram immune-suppressive tumor associated macrophages
to an anti-tumor state in preclinical studies. A Phase 1 clinical
trial, named INNATE, of JTX-8064 as a monotherapy and in
combination with pimivalimab (formerly JTX-4014), Jounce’s internal
PD-1 inhibitor, is currently enrolling patients with advanced solid
tumors. Jounce’s most advanced product candidate, vopratelimab, is
a monoclonal antibody that binds to and activates ICOS, and is
currently being studied in the SELECT Phase 2 trial. Pimivalimab is
a PD-1 inhibitor intended for combination use in the INNATE and
SELECT trials and with Jounce’s broader pipeline. Additionally,
Jounce obtained IND clearance for and exclusively licensed
worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8
and designed to selectively deplete T regulatory cells in the tumor
microenvironment, to Gilead Sciences, Inc. For more information,
please visit www.jouncetx.com.
Investor and Media Contacts:
Mark YoreJounce Therapeutics, Inc.+1-857-200-1255
myore@jouncetx.com
Julie SeidelStern Investor
Relations+1-212-362-1200Julie.Seidel@sternir.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Apr 2023 to Apr 2024